Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

A rally in big tech stocks led the broader market to a higher close Wednesday, lifting the Nasdaq to an all-time high and ...

Verona brings with it Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, often known as smoker's lung ...